PRF Technologies

PRFX · NASDAQ

$0.7246+$0.0126 (+1.77%)TodayMarket closed · Oct 20, 4:00 PM ET

Prev close $0.712

About PRFX

PRF Technologies Ltd. is a pharmaceutical company, which focuses on reformulation of established therapeutics. The company employs 6 full-time employees The company went IPO on 2020-09-01. The firm is a producer of speciality pharmaceuticals as well as energy analytics powered by artificial intelligence (AI). The Firm develops reformulated and sustained‑release drug‑delivery platforms that combine proven generic medicines with proprietary extended‑release systems to improve patient outcomes. One of the Company's products is PRF‑110 - a ropivacaine‑based formulation designed to deliver localised, extended postoperative analgesia. The firm also advances OcuRingTD, a bio‑erodible drug‑release ring integrated with intraocular lenses for continuous delivery of medications in cataract surgery.In the energy analytics sector the Company operates DeepSolar platform that provides AI‑powered monitoring, forecasting, and optimisation tools for solar asset performance.

Employees: 4
Headquarters: TEL AVIV-YAFO
Listed: Sep 1, 2020
Sector: Health Care
Industry: Pharmaceuticals
Website: prf-tech.com

Leadership

PRF Technologies executives
Name	Title	Since	Age
Ehud Geller	—	2008	76
Ilan Hadar	—	—	53
Sigal Aviel	—	—	58
Prof. Eli Hazum	—	2019	73
Rita Keynan	—	—	53
Ellen Baron	—	—	69
Efi Cohen-Arazi	—	—	74
Augustine Lawlor	—	—	70

Similar companies

Companies in the same industry as PRF Technologies

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.